Skip to main content

Table 1 Demographic, clinical and pathological features of study population

From: Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

Demographic data

Group

P value

Control (n = 27)

Intervention (n = 25)

Age (mean ± SD)

45.0 ± 8.36

41.0 ± 8.61

0.099

Weight (mean ± SD)

68.0 ± 9.52

70.0 ± 9.71

0.45

BMI (mean ± SD)

27.4 ± 4.37

27.7 ± 4.03

0.78

BSA (mean ± SD)

1.7 ± 0.1

1.7 ± 0.13

0.35

Positive family history n (%)

8 (29.6)

6 (24.0)

0.65

Regular Menstruation n (%)

20 (74.1)

21 (84.0)

0.38

Married n (%)

26 (96.0)

22 (88.0)

0.34

Parity (mean±SD)

2.8 ± 1.96

1.88 ± 1.36

0.069

Primary tumor size mm (mean±SD)

31.3 ± 19.54

41.2 ± 32.78

0.364

Initial T-stage n (%)

 TI

7 (25.9)

4 (16.0)

0.611

 T2

6 (22.2)

9 (36.0)

 T3

4 (14.8)

5 (20.0)

 T4

10 (37.0)

7 (28.0)

Tumor grade n (%)

 I

6 (22.2)

3 (12.0)

0.657

 II

13 (48.1)

13 (52.0)

 III

8 (29.6)

9 (36.0)

Node involvement n (%)

21 (77.7)

22 (88.0)

0.469

Hormonal status

 ER+ n (%)

21 (85.0)

23 (84.0)

1.00

 Extent of positivity (mean±SD)

74.3 ± 25.1

59.9 ± 33.9

0.104

 PR+ n (%)

19 (70.0)

14 (56.0)

0.28

 Extent of positivity (mean±SD)

48.7 ± 32.7

46.78 ± 32.7

0.869

HER2+ n (%)

10 (37.0)

8 (32.0)

0.43

ki67+a n (%)

15 (55.5)

19 (76.0)

0.122

ki67 (mean±SD)

34.8 ± 27.8

37.2 ± 23.7

0.742

Molecular Subtype

 HR+/HER2-

12 (44.4%)

9 (36%)

0.98

 HR+/HER2+

11 (40.1%)

12 (48%)

 HR-/HER2+

2 (7.4%)

2 (8%)

 TNBC

2 (7.4%)

2 (8%)

TILb n (%)

+

13 (48.1)

10 (40.0)

0.554

-

14 (51.9)

15 (60.0)

  1. BMI Body mass index, BSA Body surface area, ER Estrogen receptor, PR Progesterone receptor, NACT neoadjuvant chemotherapy, TNBC Triple negative breast cancer, TIL Tumor-infiltrating lymphocytes
  2. aCut-off for ki67 positivity was 20%
  3. bCut-off for TIL was 10%